title: Vitamin K antagonists are hard to beat by the price - are they? Some answers, new questions and the GPs dilemma.
authors.forename: Jürg H
authors.initials: JH
authors.lastname: Beer
mesh_terms: D000933:Antifibrinolytic Agents / Q000191:economics* / Q000627:therapeutic use; D000991:Antithrombins / Q000191:economics / Q000627:therapeutic use; D002755:Choice Behavior; D003362:Cost-Benefit Analysis; D004305:Dose-Response Relationship, Drug; D058006:General Practice; D006801:Humans; D019057:Quality-Adjusted Life Years; D013557:Switzerland; D061665:Time-to-Treatment; D014812:Vitamin K / Q000191:economics* / Q000627:therapeutic use
chemical_list: D000933:Antifibrinolytic Agents; D000991:Antithrombins; D014812:Vitamin K